A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Phase 4

• Conditions: Age-Related Macular Degeneration (AMD)

• Registration Number: NCT00354445
• Lead Sponsor: Eyetech Pharmaceuticals

Brief Summary

The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-06
• Study First Submitted: 2006-07-18
• Study First Submitted QC: 2006-07-18
• Study First Posted: 2006-07-20
• Status Verified: 2007-01
• Last Update Submitted: 2007-01-12
• Last Update Posted: 2007-01-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Subfoveal CNV secondary to AMD
• At least 1 but not more than 3 prior treatments for AMD

Exclusion Criteria

• Subfoveal scar or subfoveal atrophy
• Significant media opacities, including cataract, which might interfere with visual acuity

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Retina Research Institute of Texas, LLC; 🇺🇸 Abilene, Texas, United States